Li Ge, MD
Medical Oncology · Fresno, CANPI 1194709188
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Gilead at 44.4% of the total.
Across 451 payments — averaging $42.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$9K
- Novartis$2K
- Pfizer$2K
- Daiichi Sankyo Inc.$1K
- AstraZeneca$1K
- Eisai Inc.$659
- plus $4K from 35 others
Across 45 payments — averaging $2338.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$31K
- Roche Products Limited$27K
- AstraZeneca$23K
- Seagen Inc.$17K
- Genentech, Inc.$4K
- Pfizer$3K
What the payments were for
- Consulting fees$7,18037%
- Travel & lodging$1,4708%
- Food & beverage$9,22248%
- Education$120%
- Other$1,2807%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 55 | $8,517 |
| Novartis | 44 | $2,025 |
| Pfizer | 20 | $1,831 |
| Daiichi Sankyo Inc. | 116 | $1,291 |
| AstraZeneca | 56 | $1,215 |
| Eisai Inc. | 13 | $659 |
| Lilly USA, LLC | 32 | $640 |
| Genentech USA, Inc. | 24 | $473 |
| Tersera Therapeutics LLC | 9 | $311 |
| Puma Biotechnology, Inc. | 11 | $265 |
| Myriad Genetic Laboratories, Inc. | 5 | $240 |
| Seagen Inc. | 11 | $224 |
| Merck | 6 | $130 |
| Blueprint Medicines Corporation | 1 | $122 |
| GSK | 4 | $110 |
| Caris MPI, Inc. | 4 | $100 |
| Genentech, Inc. | 1 | $98 |
| Array Biopharma Inc | 1 | $96 |
| Immunogen, Inc. | 4 | $80 |
| Stemline Therapeutics Inc. | 3 | $76 |
| Tempus AI, Inc | 3 | $73 |
| Menarini Silicon Biosystems, Inc. | 3 | $68 |
| Coherus Oncology, Inc. | 4 | $61 |
| Sobi, Inc | 2 | $54 |
| Mylan Institutional Inc. | 2 | $46 |
| Fennec Pharmaceuticals, Inc. | 2 | $41 |
| Sanofi | 1 | $31 |
| Fresenius Kabi USA, LLC | 1 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $26 |
| AbbVie | 1 | $25 |
| Accord Healthcare, Inc. | 1 | $25 |
| BD | 1 | $24 |
| Dova Pharmaceuticals | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Bristol Myers Squibb | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Heron Therapeutics, Inc. | 1 | $15 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trodelvy$7,425
- IBRANCE$1,300
- LENVIMA$413
- GAVRETO$122
- myChoice CDx$117
How this compares
$19,164 in reported general payments places this provider in the 65th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 45 | $628,188 |
| ZarxioFilgrastim-Sndz | 11 | $19,776 |
| Exemestane | 24 | $7,820 |
| Anastrozole | 276 | $5,840 |
| Tamoxifen Citrate | 65 | $1,349 |
| Alendronate Sodium | 56 | $532 |
| Letrozole | 23 | $526 |
| Prochlorperazine Maleate | 34 | $250 |
| Dexamethasone | 38 | $234 |
| Gabapentin | 15 | $193 |
| Oxycodone Hcl | 12 | $180 |
| Ondansetron Hcl | 29 | $85 |
| Levofloxacin | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $1,831 | $628,18845 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 379 medical oncology providers in California.
Other medical oncology in Fresno
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.